Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.

Eric L MattesonClive KellyJörg H W DistlerAnna-Maria Hoffmann-VoldJames R SeiboldShikha MittooPaul F DellaripaMartin Aringer Janet E Pope Oliver DistlerAlexandra JamesRozsa Schlenker-HercegSusanne StowasserManuel QuaresmaKevin R Flahertynull null

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2022)

In the INBUILD trial, nintedanib slowed the rate of decline in FVC in patients with progressive fibrosing autoimmune disease-related ILDs, with AEs that were manageable for most patients.

Keyphrases

multiple sclerosis
interstitial lung disease
phase iii
idiopathic pulmonary fibrosis
end stage renal disease
systemic sclerosis
study protocol
clinical trial
newly diagnosed
ejection fraction
chronic kidney disease
drug induced
phase ii
prognostic factors
randomized controlled trial
open label
patient reported